Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.35 |
| ▸ | PTPRA | P18433 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PTPRF | P10586 | 1/20 | 0.34 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918892 | 1.00 | PTPN1 (0.39) | PTPN1PTPN2PTPRAALDH1A1HPGD | |
| SCHEMBL3918895 | 1.00 | PTPN1 (0.39) | PTPN1PTPN2PTPRAALDH1A1HPGD | |
| SCHEMBL3915722 | 0.96 | ALDH1A1 (0.35) | PTPN1ALDH1A1HPGDL3MBTL1DRD2 | |
| SCHEMBL3915717 | 0.96 | ALDH1A1 (0.35) | PTPN1ALDH1A1HPGDL3MBTL1DRD2 | |
| SCHEMBL3915720 | 0.96 | ALDH1A1 (0.35) | PTPN1ALDH1A1HPGDL3MBTL1DRD2 | |
| SCHEMBL3918228 | 0.81 | PTPN1 (0.41) | PTPN1ALDH1A1HPGDL3MBTL1KMT2A | |
| SCHEMBL3918224 | 0.81 | PTPN1 (0.41) | PTPN1ALDH1A1HPGDL3MBTL1KMT2A | |
| SCHEMBL3918225 | 0.81 | PTPN1 (0.41) | PTPN1ALDH1A1HPGDL3MBTL1KMT2A | |
| SCHEMBL3921013 | 0.81 | MCL1 (0.42) | PTPN1ALDH1A1HPGDL3MBTL1KMT2A | |
| SCHEMBL3921009 | 0.81 | MCL1 (0.42) | PTPN1ALDH1A1HPGDL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTPN1 21/4885PTPN2 5/4885PTPRA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.